financetom
Business
financetom
/
Business
/
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Jan 7, 2025 12:13 PM

Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. ( AVR ) with a Positive rating and a forecast of $22.

The analyst notes that Anteris Technologies’ DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement (BEV TAVR) system by 2028

Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems from Medtronic plc ( MDT ). and Abbott Laboratories ( ABT ) .

The analyst points out that DurAVR, positioned as an emerging next-gen TAVR player, is on track to capture 4%-5% of the U.S. TAVR market by 2030.

Despite strong data from MDT in 2024, clinicians still favor balloon-expandable (BEV) TAVR systems, of which DurAVR is set to be the second.

Also Read: Meta Drops Fact-Checking For Community Notes: Zuckerberg Sees ‘Opportunity To Restore Free Expression’

The analyst estimates that in the U.S., around 130,000 isolated aortic valve replacement (AVR) procedures are performed annually, out of about 550,000 patients with symptomatic severe aortic stenosis (ssAS). Additionally, 175,000 new ssAS patients are diagnosed each year, while 100,000 patients die annually due to lack of treatment.

Although TAVR market growth has slowed, the analyst sees the market as underpenetrated and views it as a promising target for the next-gen DurAVR platform.

In addition to its BEV delivery system, DurAVR offers superior hemodynamics and laminar blood flow, combining the best features of leading TAVR platforms for more favorable hemodynamics and a low-profile valve height.

Early clinical evidence suggests that DurAVR could outperform other leading TAVR platforms in areas such as hemodynamics, outcomes in valve-in-valve (VIV) procedures and potentially in long-term durability, thanks to the company’s proprietary ADAPT tissue technology, Miksic writes.

For FY25, the analyst estimates the company to report a loss of $(1.30) per share.

Price Action: AVR shares are trading higher by 2.67% to $5.760 at last check Tuesday.

Read now:

AMD Unveils ‘Next Generation' AI Processors, Gaming Gear Ahead Of CES 2025

Anteris logo courtesy of company

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Polestar 9-month revenue up 49%, plans reverse stock split
Polestar 9-month revenue up 49%, plans reverse stock split
Nov 12, 2025
Overview * Polestar's 9-month revenue grows 49% to $2.17 bln, driven by higher volumes and model mix * Company reports negative gross margin of 34.5% due to non-cash impairment expense * Polestar achieves $123 mln in carbon credits sales, surpassing targets * Company plans reverse stock split to keep Nasdaq listing Outlook * Company did not provide specific guidance for...
Biotech firm PepGen's Q3 net loss narrows to $18 mln
Biotech firm PepGen's Q3 net loss narrows to $18 mln
Nov 12, 2025
Overview * PepGen ( PEPG ) Q3 net loss narrows to $18 mln from $21.4 mln in 2024 * Company raised $115 mln, extending cash runway into 2H 2027 * FREEDOM-DM1 study shows highest mean splicing correction in DM1 patients Outlook * PepGen expects FREEDOM2 5 mg/kg cohort results in Q1 2026 * Company plans to initiate 10 mg/kg dosing...
EU looks to Big Tech, influencers to fight hybrid threats, fake news
EU looks to Big Tech, influencers to fight hybrid threats, fake news
Nov 12, 2025
BRUSSELS, Nov 12 (Reuters) - Europe is looking to online platforms and influencers to help fight disinformation and promote democracy according to a European Commission strategy presented on Wednesday amid concerns over interference by foreign governments in national elections. Alphabet's Google, Microsoft ( MSFT ), Meta Platforms ( META ), Elon Musk's X, TikTok and other online platforms already have...
Medical tech firm Sanara's Q3 revenue misses estimates after Tissue Health Plus unit closure
Medical tech firm Sanara's Q3 revenue misses estimates after Tissue Health Plus unit closure
Nov 12, 2025
Overview * Sanara Q3 revenue grows 22% yr/yr to $26.3 mln, missing analyst expectations * Net income from continuing operations improved to $0.8 mln from a loss last year * Company ceases Tissue Health Plus operations for strategic realignment Outlook * Company expects strong, sustainable revenue growth for remainder of 2025 Result Drivers * SOFT TISSUE SALES - Revenue growth...
Copyright 2023-2026 - www.financetom.com All Rights Reserved